India, June 24 -- Absci Corporation (ABSI) stock rose 18.83 percent, gaining $1.40 to $8.81 on Wednesday, after the company reported positive interim Phase 1 clinical data for ABS-201, its investigational anti-prolactin receptor antibody developed using generative AI.
The stock is currently trading at $8.81, compared with its previous close of $7.41 on the Nasdaq. During the session, shares opened at $9.51 and traded between $8.67 and $10.84. Volume reached 17.86 million shares, significantly above the average daily volume of 4.98 million shares.
The company said the first-in-human study demonstrated a favorable safety, pharmacokinetic, and immunogenicity profile, supporting continued development in androgenetic alopecia and endometriosis...